Email updates

Keep up to date with the latest news and content from BMC Clinical Pathology and BioMed Central.

Open Access Highly Accessed Research article

Protection of early phase hepatic ischemia-reperfusion injury by cholinergic agonists

Elahé T Crockett1*, James J Galligan2, Bruce D Uhal1, Jack Harkema3, Robert Roth2 and Kinnari Pandya1

Author Affiliations

1 Departments of Physiology & Division of Human Pathology, College of Human Medicine, Michigan State University, East Lansing, USA

2 Department of Pharmacology, College of Human Medicine, Michigan State University, East Lansing, USA

3 Department of Pathology, College of Veterinary Medicine, Michigan State University, East Lansing, USA

For all author emails, please log on.

BMC Clinical Pathology 2006, 6:3  doi:10.1186/1472-6890-6-3

Published: 15 February 2006

Abstract

Background

Cytokine production is critical in ischemia/reperfusion (IR) injury. Acetylcholine binds to macrophages and inhibits cytokine synthesis, through the cholinergic anti-inflammatory pathway. This study examined the role of the cholinergic pathway in cytokine production and hepatic IR- injury.

Methods

Adult male mice underwent 90-min of partial liver ischemia followed by reperfusion. The AChR agonists (1,1-dimethyl-4-phenyl-L-pioperazinium-iodide [DMPP], and nicotine) or saline-vehicle were administered i.p. before ischemia. Plasma cytokine tumor necrosis factor (TNF)-α, macrophage inflammatory protein-2, and Interleukin-6 were measured. Liver injury was assessed by plasma alanine transaminase (ALT) and liver histopathology.

Results

A reperfusion time-dependent hepatocellular injury occurred as was indicated by increased plasma-ALT and histopathology. The injury was associated with marked elevation of plasma cytokines/chemokines. Pre-ischemic treatment of mice with DMPP or nicotine significantly decreased plasma-ALT and cytokines after 3 h of reperfusion. After 6 h of reperfusion, the protective effect of DMPP decreased and reached a negligible level by 24 h of reperfusion, despite significantly low levels of plasma cytokines. Histopathology showed markedly diminished hepatocellular injury in DMPP- and nicotine-pretreated mice during the early-phase of hepatic-IR, which reached a level comparable to saline-treated mice at late-phase of IR.

Conclusion

Pharmacological modulation of the cholinergic pathway provides a means to modulate cytokine production and to delay IR-induced heaptocellular injury.